Cargando…
Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
The integrated stress response (ISR) converges on eIF2α phosphorylation to regulate protein synthesis. ISR is activated by several stress conditions, including endoplasmic reticulum (ER) stress, executed by protein kinase R-like endoplasmic reticulum kinase (PERK). We report that ER stress combined...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066181/ https://www.ncbi.nlm.nih.gov/pubmed/32161259 http://dx.doi.org/10.1038/s41467-020-15067-5 |
_version_ | 1783505193581674496 |
---|---|
author | Mahameed, Mohamed Boukeileh, Shatha Obiedat, Akram Darawshi, Odai Dipta, Priya Rimon, Amit McLennan, Gordon Fassler, Rosi Reichmann, Dana Karni, Rotem Preisinger, Christian Wilhelm, Thomas Huber, Michael Tirosh, Boaz |
author_facet | Mahameed, Mohamed Boukeileh, Shatha Obiedat, Akram Darawshi, Odai Dipta, Priya Rimon, Amit McLennan, Gordon Fassler, Rosi Reichmann, Dana Karni, Rotem Preisinger, Christian Wilhelm, Thomas Huber, Michael Tirosh, Boaz |
author_sort | Mahameed, Mohamed |
collection | PubMed |
description | The integrated stress response (ISR) converges on eIF2α phosphorylation to regulate protein synthesis. ISR is activated by several stress conditions, including endoplasmic reticulum (ER) stress, executed by protein kinase R-like endoplasmic reticulum kinase (PERK). We report that ER stress combined with ISR inhibition causes an impaired maturation of several tyrosine kinase receptors (RTKs), consistent with a partial block of their trafficking from the ER to the Golgi. Other proteins mature or are secreted normally, indicating selective retention in the ER (sERr). sERr is relieved upon protein synthesis attenuation and is accompanied by the generation of large mixed disulfide bonded complexes, including ERp44. sERr was pharmacologically recapitulated by combining the HIV-protease inhibitor nelfinavir with ISRIB, an experimental drug that inhibits ISR. Nelfinavir/ISRIB combination is highly effective to inhibit the growth of RTK-addicted cell lines and hepatocellular (HCC) cells in vitro and in vivo. Thus, pharmacological sERr can be utilized as a modality for cancer treatment. |
format | Online Article Text |
id | pubmed-7066181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70661812020-03-18 Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy Mahameed, Mohamed Boukeileh, Shatha Obiedat, Akram Darawshi, Odai Dipta, Priya Rimon, Amit McLennan, Gordon Fassler, Rosi Reichmann, Dana Karni, Rotem Preisinger, Christian Wilhelm, Thomas Huber, Michael Tirosh, Boaz Nat Commun Article The integrated stress response (ISR) converges on eIF2α phosphorylation to regulate protein synthesis. ISR is activated by several stress conditions, including endoplasmic reticulum (ER) stress, executed by protein kinase R-like endoplasmic reticulum kinase (PERK). We report that ER stress combined with ISR inhibition causes an impaired maturation of several tyrosine kinase receptors (RTKs), consistent with a partial block of their trafficking from the ER to the Golgi. Other proteins mature or are secreted normally, indicating selective retention in the ER (sERr). sERr is relieved upon protein synthesis attenuation and is accompanied by the generation of large mixed disulfide bonded complexes, including ERp44. sERr was pharmacologically recapitulated by combining the HIV-protease inhibitor nelfinavir with ISRIB, an experimental drug that inhibits ISR. Nelfinavir/ISRIB combination is highly effective to inhibit the growth of RTK-addicted cell lines and hepatocellular (HCC) cells in vitro and in vivo. Thus, pharmacological sERr can be utilized as a modality for cancer treatment. Nature Publishing Group UK 2020-03-11 /pmc/articles/PMC7066181/ /pubmed/32161259 http://dx.doi.org/10.1038/s41467-020-15067-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Mahameed, Mohamed Boukeileh, Shatha Obiedat, Akram Darawshi, Odai Dipta, Priya Rimon, Amit McLennan, Gordon Fassler, Rosi Reichmann, Dana Karni, Rotem Preisinger, Christian Wilhelm, Thomas Huber, Michael Tirosh, Boaz Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy |
title | Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy |
title_full | Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy |
title_fullStr | Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy |
title_full_unstemmed | Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy |
title_short | Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy |
title_sort | pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066181/ https://www.ncbi.nlm.nih.gov/pubmed/32161259 http://dx.doi.org/10.1038/s41467-020-15067-5 |
work_keys_str_mv | AT mahameedmohamed pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT boukeilehshatha pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT obiedatakram pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT darawshiodai pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT diptapriya pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT rimonamit pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT mclennangordon pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT fasslerrosi pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT reichmanndana pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT karnirotem pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT preisingerchristian pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT wilhelmthomas pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT hubermichael pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy AT tiroshboaz pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy |